BSG and hepatocellular carcinoma: Explorative study. HCC vs. controlsAnnexinV +, EpCAM + taMPs: 81.8%/66.7%, 0.833AnnexinV +, EpCAM +, CD147 + taMPs: 72.7%/82.3%, 0.739Validation study. HCC vs. controlsAnnexinV +, EpCAM + taMPs: 76.5%/63.3%, 0.769AnnexinV +, EpCAM +, CD133 + taMPs: 69.8%/41.4%, 0.626AnnexinV +, EpCAM +, ASGPR1 +, CD133 + taMPs: 80.0%/50.0%, 0.744Validation study. Cirrhosis vs. HCC AnnexinV +, EpCAM +, ASGPR1 + taMPs: 81.4%/46.9%, 0.732